Get the Stockscreener App
26.48
7.61%
-2.18
After Hours:
26.29
-0.19
-0.72%
Janux Therapeutics Inc stock is traded at $26.48, with a volume of 1.75M.
It is down -7.61% in the last 24 hours and up +16.70% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$28.66
Open:
$29.14
24h Volume:
1.75M
Relative Volume:
1.90
Market Cap:
$1.59B
Revenue:
$439.00K
Net Income/Loss:
$-105.64M
P/E Ratio:
-14.71
EPS:
-1.8
Net Cash Flow:
$-60.70M
1W Performance:
-7.77%
1M Performance:
+16.70%
6M Performance:
+3.04%
1Y Performance:
-51.15%
1-Day Range:
$24.91
$29.14
1-Week Range:
$24.91
$29.21
52-Week Range:
$21.73
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
26.48 | 1.72B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Janux Therapeutics price target raised to $46 from $45 at Stifel - TipRanks
JANX December 2026 Options Begin Trading - Nasdaq
Why Janux Therapeutics Inc. stock remains undervaluedJuly 2025 Breakouts & Expert-Curated Trade Recommendations - newser.com
Janux Therapeutics price target raised to $48 from $47 at Barclays - TipRanks
Buy Rating for Janux Therapeutics: Promising Data and Strong Financial Position Highlight Growth Potential - TipRanks
Janux Therapeutics Reports Strong Financial Position Amid Clinical Advancements - TipRanks
Janux Therapeutics Keeps Spending Up As Losses Narrow - Finimize
The Technical Signals Behind (JANX) That Institutions Follow - news.stocktradersdaily.com
Buy Rating on Janux Therapeutics Inc: Strong Financials and Promising Clinical Developments - TipRanks
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - BioSpace
Janux Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Promising Pipeline and Strategic Developments Justify Buy Rating for Janux Therapeutics Inc. - TipRanks
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q3 Revenue $10.0M, vs. FactSet Est of $2.9M - MarketScreener
Janux Therapeutics Q3 net loss narrows, R&D expenses rise - TradingView
Relative strength of Janux Therapeutics Inc. in sector analysisJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
Will Janux Therapeutics Inc. price bounce be sustainableRisk Management & Expert Approved Momentum Trade Ideas - newser.com
Is Janux Therapeutics Inc. stock a safe buy before earningsWeekly Investment Report & Technical Confirmation Alerts - newser.com
Can Janux Therapeutics Inc. stock surprise with earnings upsideWeekly Market Outlook & Daily Price Action Insights - newser.com
How Janux Therapeutics Inc. stock benefits from strong dollar2025 Performance Recap & Fast Moving Stock Trade Plans - fcp.pa.gov.br
Using fundamentals and technicals on Janux Therapeutics Inc.Quarterly Earnings Summary & Weekly Momentum Stock Picks - newser.com
Is Janux Therapeutics Inc. stock attractive for income investorsJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
Volume spikes in Janux Therapeutics Inc. stock – what they meanJuly 2025 Technicals & Fast Moving Trade Plans - newser.com
Janux Therapeutics, Inc. (JANX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Is Restile Ceramics Limited Stock Discounted Enough After Recent DeclinesRSI Overbought/Oversold & Fast Profit Stock Ideas - earlytimes.in
Janux Therapeutics, Inc. (JANX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
What analysts say about Janux Therapeutics Inc stockTechnology Stock Trends & Turn Data into Profits With Our Strategies - earlytimes.in
AlphaQuest LLC Has $224,000 Stock Holdings in Janux Therapeutics, Inc. $JANX - MarketBeat
Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 16,665 Shares of Stock - MarketBeat
Janux Therapeutics Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Exit strategy if you’re trapped in Janux Therapeutics Inc.Quarterly Market Review & Precise Trade Entry Recommendations - newser.com
Insider Sell: Andrew Meyer Sells Shares of Janux Therapeutics In - GuruFocus
Janux therapeutics CBO Meyer sells $500k in shares By Investing.com - Investing.com Canada
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):